Cipla Limited (CIPLA) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Cipla Limited, India's third-largest pharma company by revenue, reports Q2 FY 2026-2027 results with its EBITDA margin recovery and the US launch pipeline under close scrutiny after Q1 FY27 profitability fell sharply. The print will speak to whether the FY27 EBITDA margin guidance of 18.5% to 20% stays intact and how the generic Advair launch and the $1 billion US exit run-rate target are tracking.

Cipla Limited Q2 Results Date and Time

Cipla will announce its Q2 FY 2026-2027 results on Monday, October 27, 2026, per the company's investor-relations announcement dated 13 Oct 2026.

The earnings call is scheduled for 1600-1700 hrs IST on 27 October 2026, the same day as the results announcement.

What to expect from Cipla Limited's Q2 FY27 results

The quarter's central question is whether Cipla can bridge from Q1 FY27's 16.7% EBITDA margin toward its reaffirmed FY27 guidance of 18.5% to 20%, a plan that is H2-weighted and predicated on US launches landing on time. India enters the quarter with strong demand momentum — September 2026 was reported as the strongest month for the IPM in three years with sales rising 17.1% YoY — supporting a business that grew 12% YoY to a record Rs. 3,452 Cr in Q1 with chronic mix at 60.4%. North America is the swing factor: Q1 revenue of $162 Mn must move toward the guided ~$250 Mn per quarter exit run-rate, with the gAdvair ANDA approved on 27 Jul 2026 and launch expected in Q2 FY27 in a US market IQVIA sizes at $908 Mn. Offsetting tailwinds include the rupee's depreciation of roughly 8% in CY26, a translation benefit for the forex-linked half of revenue, and a US tariff regime that leaves generics outside Section 232 scope. The overhangs management has flagged are the 7 USFDA Form 483 observations at Pithampur from the 17-25 Aug 2026 inspection, the unresolved Lanreotide supply restoration (excluded from all FY27 guidance, with an alternate US site targeted by FY28), and an unquantified 1%-2% war-related sourcing cost impact. The upcoming call — the first with new Global CFO Dinesh Jain — will likely cover the margin bridge, gAdvair launch execution, and Pithampur remediation status.

Key Things To Watch

FY27 EBITDA margin guidance (18.5% to 20%): Q1 FY27 actual was 16.7%, below pre-Revlimid levels per analyst framing on the Q1 call.

• Whether the new CFO reaffirms, narrows, or cuts the 18.5% to 20% FY27 range, which is H2-weighted and excludes Lanreotide
• Whether Q2 sequential margin improvement tracks the H2-weighted plan, with further improvement expected in Q3/Q4 due to the winter season
• Whether the 1%-2% war-related sourcing cost impact estimate is refined or quantified

US $1 billion exit run-rate and gAdvair launch: Q1 FY27 US revenue was $162 Mn against the ~$250 Mn per quarter exit math.

• gAdvair launch execution — ANDA approved 27 Jul 2026 in 3 strengths (100/50, 250/50, 500/50 mcg), launch expected Q2 FY27; management has said Advair is not expected to be a $100 Mn product due to competition
• Timing of the key peptide launch among the four significant FY27 US launches (three respiratory assets including generic Advair plus one key peptide)
• gVentolin ramp toward full ramp-up by end of FY27, with commercial shipments commenced in Q1 FY27 and Albuterol MDI share at 21% (IQVIA week ending June 2026)

Lanreotide supply restoration: Production stopped in December after a November USFDA inspection at partner Pharmathen.

• Any update on Pharmathen remediation and USFDA re-inspection timing versus the earlier H1 FY27 re-supply expectation
• Tech transfer to an alternate US-based site targeted to restore supply by FY28; timing described as 'fluid' and not included in Q4/FY27 projections

Pithampur Form 483 observations and inspection pipeline: The follow-up cGMP inspection at Pithampur (17-25 Aug 2026) concluded with 7 Form 483 observations.

• Remediation status on the 7 observations and whether any launches or approvals are affected — management said it will address them comprehensively within stipulated time
• Indore re-inspection timing, with remediation complete and awaiting USFDA audit; one respiratory filing from Goa is already audited and clear
• Whether the New York facility's single Form 483 observation delays only smaller solid oral launches — management said the major respiratory or peptide assets should not be affected

India growth and accounting-change base effects: One India posted its highest-ever quarterly revenue of Rs. 3,452 Cr (+12% YoY) in Q1 FY27.

• Whether double-digit India growth sustains against the Q2FY26 base of Rs. 3,146 Cr, with chronic mix at 60.4% in Q1 FY27 vs 61.8% in Q2FY26
• Reported vs ~4% adjusted growth comparisons recurring in Q2 FY27 given the 1 Apr 2026 accounting change netting marketing/proportional expenditures off revenue, largely affecting South Africa
• South Africa tender recovery — tender revenue fell from $23 Mn to $14 Mn in Q1 FY27 due to last year's tender loss